CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Vyxeos;   Drug: Gemtuzumab Ozogamicin
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Jazz Pharmaceuticals
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 29, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments